Zafgen (ZFGN) Rating Lowered to Hold at Zacks Investment Research

Zacks Investment Research lowered shares of Zafgen (NASDAQ:ZFGN) from a buy rating to a hold rating in a research report released on Saturday, January 13th.

According to Zacks, “Zafgen, Inc. is a biopharmaceutical company. The Company develops therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate includes Beloranib, an injection that is in Phase II clinical trials for the treatment of various indications comprising obesity and hyperphagia in Prader-Willi Syndrome patients, craniopharyngioma-associated obesity, and severe obesity in the general population. Zafgen, Inc. is headquartered in Cambridge, Massachusetts. “

Separately, ValuEngine cut shares of Zafgen from a sell rating to a strong sell rating in a research report on Tuesday, October 10th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the stock. Zafgen has a consensus rating of Hold and an average price target of $6.63.

Zafgen (ZFGN) traded up $0.52 during mid-day trading on Friday, reaching $6.05. 156,284 shares of the company’s stock were exchanged, compared to its average volume of 156,485. Zafgen has a 1 year low of $3.21 and a 1 year high of $6.18. The company has a market capitalization of $152.02, a PE ratio of -3.34 and a beta of -1.25.

Zafgen (NASDAQ:ZFGN) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.46) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.58) by $0.12. analysts expect that Zafgen will post -2.02 earnings per share for the current fiscal year.

Institutional investors have recently made changes to their positions in the company. GSA Capital Partners LLP purchased a new stake in shares of Zafgen during the 2nd quarter valued at $259,000. Vanguard Group Inc. lifted its position in Zafgen by 15.7% in the 2nd quarter. Vanguard Group Inc. now owns 883,838 shares of the biopharmaceutical company’s stock worth $3,102,000 after buying an additional 119,902 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Zafgen by 31.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 584,159 shares of the biopharmaceutical company’s stock worth $2,050,000 after buying an additional 140,848 shares during the last quarter. OxFORD Asset Management LLP bought a new stake in Zafgen in the 2nd quarter worth approximately $364,000. Finally, Goldman Sachs Group Inc. lifted its position in Zafgen by 1,701.5% in the 2nd quarter. Goldman Sachs Group Inc. now owns 197,287 shares of the biopharmaceutical company’s stock worth $692,000 after buying an additional 186,336 shares during the last quarter. 48.60% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright and trademark laws. The original version of this piece of content can be read at https://www.truebluetribune.com/2018/01/20/zafgen-zfgn-lowered-to-hold-at-zacks-investment-research.html.

Zafgen Company Profile

Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.

Get a free copy of the Zacks research report on Zafgen (ZFGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply